Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (TSV: TLT )

0.2350 -0.0050 (-2.08%)
Streaming Delayed Price Updated: 2:57 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,300
Open 0.2350
Bid (Size) 0.2350 (120)
Ask (Size) 0.2450 (300)
Prev. Close 0.2400
Today's Range 0.2300 - 0.2400
52wk Range 0.1400 - 0.3800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile

Performance

YTD
-14.55%
-14.55%
1 Month
-12.96%
-12.96%
3 Month
-11.32%
-11.32%
6 Month
+42.42%
+42.42%
1 Year
+11.90%
+11.90%

More News

Read More
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Via Newsfile
Topics Death
Exposures Death
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Launches New Clinical Study Site in Canada
Via ACCESSWIRE
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Via ACCESS Newswire
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Via ACCESS Newswire
Theralase(R) Launches Three New Clinical Study Sites in USA
Via ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Via ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
Via ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Via ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Via ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.